New York, May 31, 2026, 13:03 EDT
- Lyell ended Friday at $17.33, gaining 2.97% for the session. Shares are down around 0.7% since the previous Friday in a week shortened by Memorial Day.
- Nasdaq Composite gained 2.4% on the week, but Lyell lagged the broader move in growth stocks.
- Lyell’s main driver is still clinical. The company says more PiNACLE data should come in the second half of 2026, then expects pivotal data in mid-2027. Lyell plans to file for FDA marketing in 2027.
Lyell Immunopharma (NASDAQ: LYEL) stock posted a late rebound to close out the short week, gaining almost 3% to finish at $17.33 on Friday. Shares moved in a $16.30 to $17.475 range, according to Investing.com. The cancer cell-therapy name lagged the broader U.S. market.
Lyell is still trading as a clinical-readout story, not on earnings. Its value depends on whether its main CAR T-cell drug, ronde-cel, can deliver enough on safety and efficacy to compete with approved therapies for large B-cell lymphoma.
CAR T-cell therapy takes a patient’s white blood cells, changes them in a lab to hunt cancer, and infuses them back into the patient. Lyell’s PiNACLE-H2H trial is putting ronde-cel up against approved CAR T-cell therapies in aggressive B-cell lymphoma.
S&P 500 gained 1.4% for the week and the Nasdaq added 2.4%, AP reported. U.S. stocks ended higher Friday as risk appetite picked up. Lyell ended the week just under its May 22 close at $17.46.
Lyell says its PiNACLE pivotal trial in third-line-or-later large B-cell lymphoma is still set to deliver more data in the second half of 2026. Meanwhile, the company has started dosing patients in the PiNACLE-H2H Phase 3 study in the second-line group, with event-free survival as the main endpoint — measuring how long patients go without issues like progression or treatment failure.
Lyell president and CEO Lynn Seely told a Stifel event the biotech has “2 lead programs in the clinic”—one for large B-cell lymphoma, another for metastatic colorectal cancer. Seely also highlighted Lyell’s manufacturing capabilities as a selling point for investors. Seeking Alpha
The competitive angle here is very clear. PiNACLE-H2H is testing ronde-cel directly against what doctors can pick: either lisocabtagene maraleucel (liso-cel) or axicabtagene ciloleucel (axi-cel). The study names those CAR-Ts as Breyanzi and Yescarta. FDA documents show Breyanzi is manufactured by Juno Therapeutics, which is part of Bristol Myers Squibb. Yescarta is sold by Kite, a Gilead company.
Krish Patel, director of lymphoma research at Sarah Cannon Research Institute, called the head-to-head trial “a milestone in the field of cellular therapy.” Lyell Chief Medical Officer David Shook said in February the company plans to submit data from the single-arm PiNACLE trial to the FDA for marketing approval next year. Lyell Immunopharma, Inc.
Lyell’s balance sheet buys some time, but not forever. The company posted a net loss of $24.2 million for the first quarter, better than its $52.2 million loss a year ago. Cash, cash equivalents and marketable securities were $261 million at March 31, which Lyell says should cover operations through the third quarter of 2027.
Stocks could take their cue from the macro picture this week, not just company headlines. Reuters said investors are waiting for the June 5 U.S. payrolls data, watching if inflation or rate worries threaten the rally. Liz Ann Sonders at Schwab Center for Financial Research told Reuters a softer payrolls number might “calm fears” of Fed tightening. Reuters
But the downside is clear. Lyell’s 10-Q says it has no approved products, doesn’t expect any product-sales revenue anytime soon and needs a lot more cash. The company also cautions that clinical data so far are limited, and later studies might not prove safety or effectiveness for approval. Shares could drop fast on weak trial data, slow patient enrollment or any safety issue.
The stock is still stuck between a firm market and the slow pace of biotech timelines. A gain on Friday helped firm things up, but June probably depends on investors’ appetite for clinical risk as they wait for more concrete data.
